Lantheus reports third quarter 2026 results and FDA approvals
FROM THE WIRE · GLOBENEWSWIRE.COM
Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 FDA approves…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAdjusted EPS rose sharply and new FDA approvals were announced, alongside a pending merger with Curium.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Worldwide revenue was 389.9 million dollars in Q3 2026.
- 02Adjusted diluted EPS was 1.68 dollars, versus 1.27 in Q3 2025.
- 03The FDA approved TAUKLARIFY and granted final approval to BRAVNETSA.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets